Vaccine maker Serum Institute of India’s CEO Adar Poonawalla on Thursday said the Oxford COVID-19 vaccine should be available for healthcare workers and elderly people by around February 2021 and by April for the general public, and will be priced at a maximum of Rs 1,000 for two necessary doses for the public, depending on the final trial results and regulatory approvals, reports The Hindu online.
Probably by 2024, every Indian would get vaccinated, he said at the Hindustan Times Leadership Summit, 2020.
Asked at what price the public will get it, he said it will be around USD 5-6 per dose with an MRP of around Rs 1,000 for the two necessary doses.
‘The government of India will be getting it at a far cheaper price at around USD 3-4, because it will be buying in a large volume and get access to the price that is similar to what COVAX has got. We are still pricing it far cheaper and more affordable than other vaccines we have in the market today,’ Poonawalla said.
Asked about the efficacy of the vaccine, he said the Oxford-Astrazeneca vaccine is so far proving to work very well even in elderly people, which was a concern earlier.
‘It has induced a good T-cell response, which is an indicator for your long-term immunity and antibody response but then again, time will only tell if these vaccines are going to protect you in the long term. Nobody can answer that for any of the vaccines today,’ Poonawalla said.
Responding to a question on the safety aspect, he said there has been no major complaints, reactions or adverse events, adding, ‘We would need to wait and see. The efficacy and immunogenicity results from the Indian trials will come out in about a month-and-a half.’
Want stories like this in your inbox?
Sign up to exclusive daily email
More Stories from South Asia